Verrica Pharmaceuticals Inc.(VRCA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VRCA Verrica Pharmaceuticals Inc.

Market Closed 12-12 16:00:00 EST

7.92

-0.38

-4.58%

盘后7.55

-0.37-4.63%

18:51 EST

High8.60	Low7.88	Vol170.59K
Open8.41	D1 Closing8.30	Amplitude8.67%
Mkt Cap126.64M	Tradable Cap15.33M	Total Shares15.99M
T/O1.38M	T/O Rate8.81%	Tradable Shares1.94M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"VRCA","market":"US","secType":"STK","nameCN":"Verrica Pharmaceuticals Inc.","latestPrice":7.92,"timestamp":1765573200000,"preClose":8.3,"halted":0,"volume":170594,"hourTrading":{"tag":"盘后","latestPrice":7.553,"preClose":7.92,"latestTime":"18:51 EST","volume":949,"amount":7250.91,"timestamp":1765583513089},"delay":0,"floatShares":1935557,"shares":15989861,"eps":-2.955175,"marketStatus":"Market Closed","change":-0.38,"latestTime":"12-12 16:00:00 EST","open":8.41,"high":8.6,"low":7.88,"amount":1384130.62543,"amplitude":0.086747,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.955175,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1529035200000,"exchange":"NASDAQ","adjPreClose":8.3,"preHourTrading":{"tag":"盘前","latestPrice":8.15,"preClose":8.3,"latestTime":"08:43 EST","volume":55,"amount":454.70163749999995,"timestamp":1765547023327},"postHourTrading":{"tag":"盘后","latestPrice":7.553,"preClose":7.92,"latestTime":"18:51 EST","volume":949,"amount":7250.91,"timestamp":1765583513089},"volumeRatio":0.8313426224258013,"impliedVol":0.3196,"impliedVolPercentile":0.4408},"requestUrl":"/m/hq/s/VRCA/wiki","defaultTab":"wiki","newsList":[{"id":"2586400526","title":"Verrica Pharmaceuticals CMO Noah L. Rosenberg Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586400526","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586400526?lang=en_us&edition=fundamental","pubTime":"2025-11-26 08:00","pubTimestamp":1764115253,"startTime":"0","endTime":"0","summary":"Noah L. Rosenberg, Chief Medical Officer of Verrica Pharmaceuticals Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL2dfrJ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2586006544","title":"Director and 10% Owner Paul B. Manning Reports Acquisition of Verrica Pharmaceuticals Inc. Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586006544","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586006544?lang=en_us&edition=fundamental","pubTime":"2025-11-26 08:00","pubTimestamp":1764115248,"startTime":"0","endTime":"0","summary":"Paul B. Manning, a Director and 10% Owner, reported the acquisition of common shares of Verrica Pharmaceuticals Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL8JmCNj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VRCA"],"gpt_icon":0},{"id":"2586005274","title":"Verrica Pharmaceuticals CEO Jayson Rieger Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586005274","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586005274?lang=en_us&edition=fundamental","pubTime":"2025-11-26 08:00","pubTimestamp":1764115245,"startTime":"0","endTime":"0","summary":"Jayson Rieger, CEO and President of Verrica Pharmaceuticals Inc., reported an acquisition of common shares of Verrica Pharmaceuticals Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL4ZQz6c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2586400528","title":"Interim CFO John J. Kirby Acquires Common Shares of Verrica Pharmaceuticals Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2586400528","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586400528?lang=en_us&edition=fundamental","pubTime":"2025-11-26 08:00","pubTimestamp":1764115243,"startTime":"0","endTime":"0","summary":"John J. Kirby, Interim CFO of Verrica Pharmaceuticals Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 25, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL7hzBdL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Interim CFO John J. Kirby Acquires Common Shares of Verrica Pharmaceuticals Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2586491049","title":"BRIEF-Verrica Pharmaceuticals Enters Securities Purchase Agreement With Institutional Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2586491049","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586491049?lang=en_us&edition=fundamental","pubTime":"2025-11-25 02:17","pubTimestamp":1764008243,"startTime":"0","endTime":"0","summary":"BRIEF-Verrica Pharmaceuticals Enters Securities Purchase Agreement With Institutional InvestorsNov 24  - Verrica Pharmaceuticals Inc VRCA.O:VERRICA PHARMACEUTICALS INC - ENTERS SECURITIES PURCHASE AGREEMENT WITH INSTITUTIONAL INVESTORS - SEC FILINGVERRICA PHARMACEUTICALS INC - TO SELL 6.5 MILLION SHARES IN PRIVATE PLACEMENT - SEC FILINGSource text: [ID:n0001193125-25-292155]Further company coverage: VRCA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2586496152","title":"Verrica Pharmaceuticals Inc - Enters Securities Purchase Agreement With Institutional Investors - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2586496152","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586496152?lang=en_us&edition=fundamental","pubTime":"2025-11-25 00:20","pubTimestamp":1764001232,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2586151496","title":"Verrica Pharmaceuticals Inc - to Sell 6.5 Mln Shares in Private Placement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2586151496","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586151496?lang=en_us&edition=fundamental","pubTime":"2025-11-25 00:20","pubTimestamp":1764001232,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nFWN3X00F5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VRCA"],"gpt_icon":0},{"id":"2585462508","title":"Verrica Pharmaceuticals Raises $50 Million in Private Placement Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2585462508","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585462508?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:00","pubTimestamp":1763989222,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals Inc. has announced a private investment in public equity  financing, raising approximately $50 million in gross proceeds before placement agent fees and offering expenses. The financing is anchored by Caligan Partners LP and PBM Capital, along with participation from new and existing investors. Caligan Partners will be entitled to designate a new member to Verrica's Board of Directors. Verrica intends to use $35 million of the net proceeds to fully repay its outstanding obligations under its Credit Agreement with OrbiMed, with the remainder allocated to working capital and general corporate purposes. The financing is expected to close on or about November 25, 2025, subject to customary closing conditions. With the proceeds from this financing and existing cash, Verrica expects to fund its operations into mid-2027. TD Cowen is acting as the sole placement agent for the PIPE financing.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nNDL4J6Zg4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","LU2210150020.SGD","LU2095319765.USD","BK4007","IE00BGHQF748.EUR","BK4588","IE00BKPKM429.USD","VRCA","NDAQ","LU2210149790.SGD","BK4585","BK4112"],"gpt_icon":0},{"id":"2585546233","title":"Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway","url":"https://stock-news.laohu8.com/highlight/detail?id=2585546233","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585546233?lang=en_us&edition=fundamental","pubTime":"2025-11-24 21:00","pubTimestamp":1763989203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251124:nTUA4VM8KF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VRCA"],"gpt_icon":0},{"id":"2584983010","title":"Lytix Biopharma reports promising clinical results for ruxotemitide in melanoma and basal cell carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2584983010","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584983010?lang=en_us&edition=fundamental","pubTime":"2025-11-18 14:00","pubTimestamp":1763445652,"startTime":"0","endTime":"0","summary":"Cash and short-term financial investments at Lytix Biopharma AS amounted to NOK 90.0 million as of September 30, 2025. The reported net loss was temporarily increased by a non-cash share option expense of NOK 11.9 million related to a new option program launched in September. During the period, Lytix advanced ruxotemitide toward commercialization through internal work in neoadjuvant melanoma and a partnership with Verrica Pharmaceuticals for the non-surgical treatment of basal cell carcinoma. The company is also expanding into deep-seated tumors with LTX-401, supported by positive pre-clinical data and regulatory feedback, and is developing a strategic plan for further clinical development.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL7VXFbS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VRCA"],"gpt_icon":0},{"id":"2583681748","title":"Verrica Pharmaceuticals reports $14.3 million revenue in third quarter 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681748","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681748?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:05","pubTimestamp":1763154325,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals Inc. reported total revenue of $14.3 million for the third quarter of 2025, including $3.6 million in YCANTH revenue and $10.7 million in license and collaboration revenue. For the nine months ended September 30, 2025, product revenue, net was $11.6 million, up from $6.3 million for the same period in 2024, primarily due to increased deliveries of YCANTH. License and collaboration revenue for the nine-month period was $18.9 million, compared to $1.0 million in the prior year, with $18.0 million attributed to milestone revenue from Torii. As of September 30, 2025, Verrica had $21.1 million in cash and cash equivalents. Recent business developments include positive feedback from the FDA regarding the Phase 3 program design for VP-315 in basal cell carcinoma, new data presented for VP-315, and a $10 million milestone payment received for the approval of YCANTH in Japan. The company also received supportive feedback from the European Medicines Agency for a Marketing","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDLbTGl1x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","BK4588","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","LU2210150020.SGD","BK4007","NDAQ","VRCA","LU2095319765.USD","BK4112"],"gpt_icon":0},{"id":"2583843966","title":"Verrica Pharmaceuticals Inc - Qtrly Net Loss per Share, Basic and Diluted $0.03","url":"https://stock-news.laohu8.com/highlight/detail?id=2583843966","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583843966?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:05","pubTimestamp":1763154301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX3AD0C2:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VRCA"],"gpt_icon":0},{"id":"2583812476","title":"Verrica Pharmaceuticals Q3 Income From Operations USD 1.627 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583812476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583812476?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:05","pubTimestamp":1763154301,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nPLX3AD0C2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRCA","BK4007"],"gpt_icon":0},{"id":"2582799178","title":"Verrica Pharmaceuticals Reports Positive Phase 2 Results for VP-315 in Basal Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2582799178","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582799178?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:00","pubTimestamp":1762779629,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals Inc. has announced new data from its Phase 2 clinical trial evaluating VP-315 , a novel oncolytic peptide immunotherapy for basal cell carcinoma . The results were presented at the 40th Annual Meeting of the Society for Immunotherapy of Cancer, held November 5-9, 2025. Findings from the exploratory analysis indicate that VP-315 reprograms the tumor microenvironment by increasing cytotoxic T-cell infiltration and reducing immunosuppressive regulatory T-cells. The data also show a 97% calculated objective response rate and a 51% complete histologic clearance rate. VP-315 is administered intratumorally and is being developed as a potential first-in-class, non-surgical immunotherapeutic option for patients with BCC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL7NqzT3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","IE00B64PRP62.GBP","VRCA","BK4585","LU2095319765.USD","BK4007","BK4588","LU2210149790.SGD","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2582879453","title":"Verrica Pharmaceuticals Presents New Data on Vp-315 From Its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40TH Society for Immunotherapy of Cancer Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2582879453","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582879453?lang=en_us&edition=fundamental","pubTime":"2025-11-10 21:00","pubTimestamp":1762779603,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nTUA2X1GM6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","VRCA"],"gpt_icon":0},{"id":"2582984141","title":"Lytix Biopharma Reports Strong Phase II Results for Ruxotemitide in Basal Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2582984141","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582984141?lang=en_us&edition=fundamental","pubTime":"2025-11-10 14:00","pubTimestamp":1762754446,"startTime":"0","endTime":"0","summary":"Lytix Biopharma AS and its partner Verrica have announced new clinical data from the Phase II study of ruxotemitide in basal cell carcinoma . Results from this study were presented at SITC 2025, demonstrating a 97% calculated objective response rate and a 51% complete histologic clearance rate. The study also showed that ruxotemitide was well-tolerated and induced strong increases in cytotoxic CD8 and helper CD4 T cells, as well as B-cell infiltration, with a reduction in T-regulatory cells in the tumor microenvironment. These findings support further evaluation of ruxotemitide in a pivotal Phase III program in BCC. Additionally, interim results from the NeoLIPA Phase II study in melanoma will be presented at the Nordic Melanoma Meeting in Troms on November 11, 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDLbR0290:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VRCA"],"gpt_icon":0},{"id":"2579463135","title":"Verrica Pharmaceuticals Inc  expected to post a loss of 67 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2579463135","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579463135?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:14","pubTimestamp":1761909249,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals Inc  expected to post a loss of67cents a share - Earnings Preview Verrica Pharmaceuticals Inc VRCA.OQ VRCA.O is expected to  show a rise in quarterly revenue when it reports  r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC0YW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","VRCA"],"gpt_icon":0},{"id":"2577963088","title":"Verrica Pharmaceuticals Cleared to File for EU Approval of Molluscum Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2577963088","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577963088?lang=en_us&edition=fundamental","pubTime":"2025-10-21 05:11","pubTimestamp":1760994694,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals  said Monday it received positive feedback from the European Medicines Agency supporting a marketing application for YCANTH, its treatment for molluscum contagiosum, in the European Union.The agency's Committee for Medicinal Products for Human Use said Verrica's prior Phase 3 studies in the US and Japan are adequate to support the filing and that no additional Phase 3 trials are required, Verrica said.The company plans to submit the application as early as Q4 2026.YCANTH, which contains cantharidin, is the first and only Food and Drug Administration-approved treatment for molluscum contagiosum in adults and children aged two years and older.Verrica Pharmaceuticals were down 8.25% in Monday after hours trading.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4156","BK4007","VRCA"],"gpt_icon":0},{"id":"2577895071","title":"Verrica Pharmaceuticals announces CHMP support for Ycanth MAA filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2577895071","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577895071?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:45","pubTimestamp":1760993112,"startTime":"0","endTime":"0","summary":"Verrica Pharmaceuticals (VRCA) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has provided feed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/verrica-pharmaceuticals-announces-chmp-support-for-ycanth-maa-filing-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/verrica-pharmaceuticals-announces-chmp-support-for-ycanth-maa-filing-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4007","VRCA","MAA","BK4087","BK4585","CHMP","BK4215"],"gpt_icon":0},{"id":"2577893203","title":"BRIEF-Verrica Pharmaceuticals Receives Positive Feedback From The European Medicines Agency (EMA) Supporting A Clear Regulatory Path Forward To File For Approval Of Ycanth® In The European Union","url":"https://stock-news.laohu8.com/highlight/detail?id=2577893203","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577893203?lang=en_us&edition=fundamental","pubTime":"2025-10-21 04:29","pubTimestamp":1760992190,"startTime":"0","endTime":"0","summary":"BRIEF-Verrica Pharmaceuticals Receives Positive Feedback From The European Medicines Agency (EMA) Supporting A Clear Regulatory Path Forward To File For Approval Of Ycanth In The European UnionOct 20 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nTUA509VPF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRCA","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.verrica.com","stockEarnings":[{"period":"1week","weight":-0.101},{"period":"1month","weight":1.0733},{"period":"3month","weight":0.6674},{"period":"6month","weight":0.2711},{"period":"1year","weight":-0.0132},{"period":"ytd","weight":0.1314}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.09626},{"month":2,"riseRate":0.571429,"avgChangeRate":0.080901},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.058304},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.016247},{"month":5,"riseRate":0.285714,"avgChangeRate":-0.140402},{"month":6,"riseRate":0.571429,"avgChangeRate":0.076173},{"month":7,"riseRate":0.5,"avgChangeRate":0.012098},{"month":8,"riseRate":0.5,"avgChangeRate":-0.04466},{"month":9,"riseRate":0.25,"avgChangeRate":-0.080364},{"month":10,"riseRate":0.125,"avgChangeRate":-0.088008},{"month":11,"riseRate":0.5,"avgChangeRate":0.227615},{"month":12,"riseRate":0.375,"avgChangeRate":0.016127}],"exchange":"NASDAQ","name":"Verrica Pharmaceuticals Inc.","nameEN":"Verrica Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Verrica Pharmaceuticals Inc.(VRCA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Verrica Pharmaceuticals Inc.(VRCA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Verrica Pharmaceuticals Inc.,VRCA,Verrica Pharmaceuticals Inc.股票,Verrica Pharmaceuticals Inc.股票老虎,Verrica Pharmaceuticals Inc.股票老虎国际,Verrica Pharmaceuticals Inc.行情,Verrica Pharmaceuticals Inc.股票行情,Verrica Pharmaceuticals Inc.股价,Verrica Pharmaceuticals Inc.股市,Verrica Pharmaceuticals Inc.股票价格,Verrica Pharmaceuticals Inc.股票交易,Verrica Pharmaceuticals Inc.股票购买,Verrica Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Verrica Pharmaceuticals Inc.(VRCA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Verrica Pharmaceuticals Inc.(VRCA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction